BHR - LHRH agonist injections for prostate cancer: advice from BHRUT

LHRH agonist therapy is an integral part of the management of a large proportion of the prostate cancers treated at BHRUT. In the current situation with regards to the Covid-19 pandemic, in order to minimise patient attendances at GP surgeries, the Trust’s Oncology leads are recommending that all patients currently receiving monthly LHRH agonist preparations be switched over at the time of their next injection to a three monthly preparation.

Patients on long term LHRH agonist therapy for relapsed or metastatic disease can be considered for six monthly Decapeptyl injections if this is available on your formulary. 

Please read the letter for more detailed advice